ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC
- Written by PR Newswire
- PRO1184 first-in human study initiated and first patients dosed
- PRO1160 first-in-human study cleared for initiation in the US
- Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform
SUZHOU, China and WOODINVILLE, Wash., Jan. 3, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...
